Evommune Inc (EVMN)

$20.69 +0.96 (4.87%)
Market Cap 710.64M
Revenue (ttm) 13.00M
Net Income (ttm) -68.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -529.77%
Debt to Equity Ratio 0.00
Volume 440,300
Avg Vol 350,324
Day's Range N/A - N/A
Shares Out 36.02M
Stochastic %K 25%
Beta N/A
Analysts Strong Sell
Price Target $52.00

Company Profile

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Industry: Biotechnology
Sector: Healthcare
Phone: (925) 247-4481
Address:
1841 Page Mill Road, Suite 100, Palo Alto, United States
ParallelPort
ParallelPort Jun. 4 at 1:14 AM
$EVMN Disregard the last post👇 After reading through all these transactons were pursuant to rule 10b5-1 and all these sells were set up in march.👍
0 · Reply
ParallelPort
ParallelPort Jun. 4 at 12:59 AM
$EVMN Looks like EVMN executives selling hand over fist.... to be positive on a stock this is not good. This thing might get crushed tomorrow.
1 · Reply
ParallelPort
ParallelPort Jun. 3 at 4:04 PM
$EVMN Wed. 12.00 pm. 45,000 volume...240 sell--1,267 buys and over 43,000 neutral. Am i worried about this price movement...not at all. If it were heavy selling then yes, but it's not. Just algos pulling triggers.
0 · Reply
Timefortendies77
Timefortendies77 Jun. 2 at 1:57 PM
$EVMN Data coming this month
0 · Reply
Timefortendies77
Timefortendies77 May. 29 at 2:02 PM
$EVMN This is a crappy stock to trade, wide spreads, and really it just sits. Little volume. That will change if things go well.
0 · Reply
laaarsas
laaarsas May. 29 at 7:42 AM
$EVMN After some more research I think a deepening response until week 12 could happen. An effect size in the range of Barzol seems possible and a bet on that seems justified. My main problem is liver tox. Nice that 300 mg is not in ph2b but it does not exclude it happening.
0 · Reply
laaarsas
laaarsas May. 28 at 9:10 PM
$EVMN I’m a bit concerned about efficacy at week 12. Why should we see a deepening response with 756? For Barzol, maybe it makes more sense since it’s mast cell depletion. But this is just a blockade. What do you think?
0 · Reply
laaarsas
laaarsas May. 27 at 10:01 PM
$EVMN How do you feel about tox for the CSU trial? Negative liver signal has been observed. A bit annoying.
1 · Reply
Timefortendies77
Timefortendies77 May. 23 at 2:32 PM
$EVMN Big data coming but wide spreads in this stock so if you buy you are committing.
1 · Reply
Timefortendies77
Timefortendies77 May. 22 at 12:11 PM
$EVMN One more week until June.
1 · Reply
Latest News on EVMN
Evommune Transcript: AGM 2026

Jun 2, 2026, 11:30 AM EDT - 2 days ago

Evommune Transcript: AGM 2026

Evommune price target raised to $55 from $54 at Morgan Stanley

2026-05-11T15:52:55.000Z - 24 days ago

Evommune price target raised to $55 from $54 at Morgan Stanley

Evommune reports Q1 EPS (64c), consensus (71c)

2026-05-07T22:50:50.000Z - 4 weeks ago

Evommune reports Q1 EPS (64c), consensus (71c)

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

May 7, 2026, 4:05 PM EDT - 4 weeks ago

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Evommune Quarterly report: Q1 2026

Evommune Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Evommune Earnings release: Q1 2026

Evommune Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Evommune Slides: Corporate presentation

Evommune initiated with a Buy at Stifel

2026-04-30T20:39:05.000Z - 5 weeks ago

Evommune initiated with a Buy at Stifel

Evommune Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Evommune Proxy statement: Proxy filing

Evommune Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Evommune Proxy statement: Proxy filing

Evommune Registration statement: Registration filing

Apr 17, 2026, 8:00 AM EDT - 6 weeks ago

Evommune Registration statement: Registration filing

Evommune Transcript: Status update

Apr 13, 2026, 2:00 PM EDT - 7 weeks ago

Evommune Transcript: Status update

Evommune assumed with an Outperform at Oppenheimer

2026-04-07T14:18:01.000Z - 2 months ago

Evommune assumed with an Outperform at Oppenheimer

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Apr 6, 2026, 9:00 AM EDT - 2 months ago

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Evommune price target lowered to $50 from $65 at H.C. Wainwright

2026-03-18T10:12:14.000Z - 2 months ago

Evommune price target lowered to $50 from $65 at H.C. Wainwright

Evommune initiated with a Buy at Clear Street

2026-03-17T20:25:28.000Z - 2 months ago

Evommune initiated with a Buy at Clear Street

Evommune initiated with an Outperform at RBC Capital

2026-03-10T10:11:40.000Z - 3 months ago

Evommune initiated with an Outperform at RBC Capital

Evommune reports Q4 EPS ($1.43), consensus (84c)

2026-03-05T21:06:11.000Z - 3 months ago

Evommune reports Q4 EPS ($1.43), consensus (84c)

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Mar 5, 2026, 4:01 PM EST - 3 months ago

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 3 months ago

Evommune Earnings release: Q4 2025

Evommune Annual report: Q4 2025

Mar 5, 2026, 7:00 AM EST - 3 months ago

Evommune Annual report: Q4 2025

Evommune Slides: Corporate presentation

Mar 5, 2026, 7:00 AM EST - 3 months ago

Evommune Slides: Corporate presentation

Evommune price target raised to $54 from $36 at Morgan Stanley

2026-02-18T18:20:32.000Z - 3 months ago

Evommune price target raised to $54 from $36 at Morgan Stanley

Evommune announces $125M private placement

2026-02-13T01:35:10.000Z - 4 months ago

Evommune announces $125M private placement

Evommune Announces $125 Million Private Placement

Feb 12, 2026, 8:30 PM EST - 4 months ago

Evommune Announces $125 Million Private Placement

Evommune price target raised to $55 from $40 at Evercore ISI

2026-02-10T18:36:15.000Z - 4 months ago

Evommune price target raised to $55 from $40 at Evercore ISI

Evommune price target raised to $65 from $35 at H.C. Wainwright

2026-02-10T17:55:11.000Z - 4 months ago

Evommune price target raised to $65 from $35 at H.C. Wainwright

Evommune jumps 67% to $28.13 after atopic dermatitis data

2026-02-10T13:37:36.000Z - 4 months ago

Evommune jumps 67% to $28.13 after atopic dermatitis data

Evommune Transcript: Study result

Feb 10, 2026, 8:30 AM EST - 4 months ago

Evommune Transcript: Study result

Evommune Press release: Study result

Feb 10, 2026, 8:30 AM EST - 4 months ago

Evommune Press release: Study result

Evommune Slides: Study result

Feb 10, 2026, 8:30 AM EST - 4 months ago

Evommune Slides: Study result

Evommune reports EVO301 trial met primary endpoint

2026-02-10T12:40:58.000Z - 4 months ago

Evommune reports EVO301 trial met primary endpoint

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Feb 10, 2026, 7:30 AM EST - 4 months ago

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis

Evommune management to meet with Oppenheimer

2026-01-28T20:55:32.000Z - 4 months ago

Evommune management to meet with Oppenheimer

Evommune Slides: Corporate presentation

Jan 7, 2026, 7:00 AM EST - 5 months ago

Evommune Slides: Corporate presentation

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Dec 11, 2025, 4:05 PM EST - 6 months ago

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update

Evommune Quarterly report: Q3 2025

Dec 11, 2025, 4:00 PM EST - 6 months ago

Evommune Quarterly report: Q3 2025

Evommune Earnings release: Q3 2025

Dec 11, 2025, 4:00 PM EST - 6 months ago

Evommune Earnings release: Q3 2025

Evommune Slides: Corporate Presentation

Dec 11, 2025, 4:00 PM EST - 6 months ago

Evommune Slides: Corporate Presentation

Evommune Announces Pricing of its Initial Public Offering

Nov 5, 2025, 7:45 PM EST - 7 months ago

Evommune Announces Pricing of its Initial Public Offering

Evommune Announces Commencement of Initial Public Offering

Oct 30, 2025, 6:30 AM EDT - 7 months ago

Evommune Announces Commencement of Initial Public Offering

Evommune Registration statement: Registration Filing

Oct 17, 2025, 8:00 AM EDT - 8 months ago

Evommune Registration statement: Registration Filing

Evommune files for IPO to advance immune drug work

Oct 10, 2025, 8:31 AM EDT - 8 months ago

Evommune files for IPO to advance immune drug work

Evommune IPO Registration Document (S-1)

Oct 9, 2025, 2:18 PM EDT - 8 months ago

Evommune IPO Registration Document (S-1)

Chronic inflammatory disease biotech Evommune files for a $100 million IPO

Oct 9, 2025, 10:32 AM EDT - 8 months ago

Chronic inflammatory disease biotech Evommune files for a $100 million IPO

ParallelPort
ParallelPort Jun. 4 at 1:14 AM
$EVMN Disregard the last post👇 After reading through all these transactons were pursuant to rule 10b5-1 and all these sells were set up in march.👍
0 · Reply
ParallelPort
ParallelPort Jun. 4 at 12:59 AM
$EVMN Looks like EVMN executives selling hand over fist.... to be positive on a stock this is not good. This thing might get crushed tomorrow.
1 · Reply
ParallelPort
ParallelPort Jun. 3 at 4:04 PM
$EVMN Wed. 12.00 pm. 45,000 volume...240 sell--1,267 buys and over 43,000 neutral. Am i worried about this price movement...not at all. If it were heavy selling then yes, but it's not. Just algos pulling triggers.
0 · Reply
Timefortendies77
Timefortendies77 Jun. 2 at 1:57 PM
$EVMN Data coming this month
0 · Reply
Timefortendies77
Timefortendies77 May. 29 at 2:02 PM
$EVMN This is a crappy stock to trade, wide spreads, and really it just sits. Little volume. That will change if things go well.
0 · Reply
laaarsas
laaarsas May. 29 at 7:42 AM
$EVMN After some more research I think a deepening response until week 12 could happen. An effect size in the range of Barzol seems possible and a bet on that seems justified. My main problem is liver tox. Nice that 300 mg is not in ph2b but it does not exclude it happening.
0 · Reply
laaarsas
laaarsas May. 28 at 9:10 PM
$EVMN I’m a bit concerned about efficacy at week 12. Why should we see a deepening response with 756? For Barzol, maybe it makes more sense since it’s mast cell depletion. But this is just a blockade. What do you think?
0 · Reply
laaarsas
laaarsas May. 27 at 10:01 PM
$EVMN How do you feel about tox for the CSU trial? Negative liver signal has been observed. A bit annoying.
1 · Reply
Timefortendies77
Timefortendies77 May. 23 at 2:32 PM
$EVMN Big data coming but wide spreads in this stock so if you buy you are committing.
1 · Reply
Timefortendies77
Timefortendies77 May. 22 at 12:11 PM
$EVMN One more week until June.
1 · Reply
ParallelPort
ParallelPort May. 21 at 8:50 PM
$EVMN Closed above the 200 day moving average today. Holding 23.50 at close was nice. Next open market movement crossing 24.00 should see the next pocket come pretty quick to around 25.50
2 · Reply
Timefortendies77
Timefortendies77 May. 21 at 11:23 AM
$EVMN So essentially Phase 2b is like their moonshot and success would completely re-rate this stock? Not that much action here with this big readout coming in June--but huge potential for this drug.
1 · Reply
ParallelPort
ParallelPort May. 20 at 9:03 PM
$EVMN I am posting the following events here that will take place over the next month. There is a shareholder meeting on June 2nd but nothing substantial should come from that. But the first conference is the American Headache Society (AHS) Annual Meeting Dates: June 4 – 7, 2026 The Target: EVO756 in Migraine Prophylaxis Significance: While we are focused on hives (CSU), EVO756 is a dual-mechanism molecule that targets both mast cells and peripheral sensory neurons. Evommune is showcasing its pipeline depth here by presenting new translational data on MRGPRX2's role in neurogenic inflammation and migraines. Management has also stated they plan to initiate a dedicated Phase 2b trial for migraine prophylaxis in mid-2026, so this conference will serve as the official marketing launch for that program.
1 · Reply
ParallelPort
ParallelPort May. 20 at 9:03 PM
$EVMN The second forum is the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting Dates: June 9 – 12, 2026 (San Francisco, CA) The Target: EVO756 in Chronic Inducible Urticaria (CIndU) Significance: This is the critical "prelude" to the binary event. Evommune is presenting two distinct scientific posters highlighting shared pathology data and tissue-level mast cell activity. This data will reinforce the biological proof-of-concept for how effectively their oral small molecule shuts down chronic hives, directly setting the stage for the top-line results.
0 · Reply
ParallelPort
ParallelPort May. 20 at 9:02 PM
$EVMN If you are looking for a date for the next data release. Enrollment is Already 100% Complete: In their May 7 update, management explicitly stated that enrollment for this N=160 patient study is fully complete. The 12-week dosing periods for the final patients are wrapping up right now. The 12-Week + 2-Week Window: The trial design requires patients to take a once-daily oral dose for 12 weeks, followed by a final safety evaluation 2 weeks after their last dose. Because the final patient was randomized weeks ago, the database lock and unblinding process are mathematically bound to occur by early-to-mid June.
0 · Reply
ParallelPort
ParallelPort May. 19 at 2:20 PM
$EVMN Add all you can here under $22 Two conferences and data read out in less than a month.
2 · Reply
S_Franconi
S_Franconi May. 17 at 2:39 AM
$EVMN @Trainguy1 @Catlover37
0 · Reply
forprofit12
forprofit12 May. 6 at 3:14 PM
$EVMN added. Might add more along the way
0 · Reply
laaarsas
laaarsas Apr. 30 at 11:11 AM
$EVMN when do we expect data what do we expect?
1 · Reply
laaarsas
laaarsas Apr. 29 at 5:55 PM
$EVMN I don't think this is a clear homerun, but it's interesting.
1 · Reply
laaarsas
laaarsas Apr. 29 at 5:24 PM
$EVMN Ok donkey squad have I finally found something that could be interesting? Upcoming readout seems promising
0 · Reply
laaarsas
laaarsas Apr. 29 at 4:06 PM
$EVMN Hi donkeys what do you think about this case?
0 · Reply